Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization.

Schueler J, Tschuch C, Klingner K, Bug D, Peille AL, de Koning L, Oswald E, Klett H, Sommergruber W.

Cells. 2019 Jul 18;8(7). pii: E740. doi: 10.3390/cells8070740.

2.

Patient derived renal cell carcinoma xenografts exhibit distinct sensitivity patterns in response to antiangiogenic therapy and constitute a suitable tool for biomarker development.

Schueler J, Klingner K, Bug D, Zoeller C, Maier A, Dong M, Willecke K, Peille AL, Steiner E, Landesfeind M, Copland JA, Siegers GM, Haferkamp A, Boehm K, Tsaur I, Schneider M.

Oncotarget. 2018 Jul 24;9(57):30946-30961. doi: 10.18632/oncotarget.25697. eCollection 2018 Jul 24.

3.

Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.

Schnerch D, Schüler J, Follo M, Felthaus J, Wider D, Klingner K, Greil C, Duyster J, Engelhardt M, Wäsch R.

Oncotarget. 2017 Mar 28;8(13):21153-21166. doi: 10.18632/oncotarget.15503.

4.

Depletion of Mouse Cells from Human Tumor Xenografts Significantly Improves Downstream Analysis of Target Cells.

Agorku DJ, Tomiuk S, Klingner K, Wild S, Rüberg S, Zatrieb L, Bosio A, Schueler J, Hardt O.

J Vis Exp. 2016 Jul 29;(113). doi: 10.3791/54259.

5.

Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell-Engaging Antibody and CD8 T Cells.

Prasad S, Gaedicke S, Machein M, Mittler G, Braun F, Hettich M, Firat E, Klingner K, Schüler J, Wider D, Wäsch RM, Herold-Mende C, Elsässer-Beile U, Niedermann G.

Cancer Res. 2015 Jun 1;75(11):2166-76. doi: 10.1158/0008-5472.CAN-14-2415. Epub 2015 Apr 3.

6.

Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells.

Gaedicke S, Braun F, Prasad S, Machein M, Firat E, Hettich M, Gudihal R, Zhu X, Klingner K, Schüler J, Herold-Mende CC, Grosu AL, Behe M, Weber W, Mäcke H, Niedermann G.

Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):E692-701. doi: 10.1073/pnas.1314189111. Epub 2014 Jan 27.

7.

Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies.

Schueler J, Wider D, Klingner K, Siegers GM, May AM, Wäsch R, Fiebig HH, Engelhardt M.

PLoS One. 2013 Nov 6;8(11):e79939. doi: 10.1371/journal.pone.0079939. eCollection 2013.

8.

Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model.

Wehr C, Müller F, Schüler J, Tomann T, Nitschke C, Seismann H, Spillner E, Klingner K, Schneider-Merck T, Binder M, Fiebig HH, Mertelsmann R, Trepel M.

Int J Cancer. 2012 Jul 15;131(2):E10-20. doi: 10.1002/ijc.26464. Epub 2011 Nov 19.

Supplemental Content

Loading ...
Support Center